Cancer gene therapy: Scientific basis

被引:45
作者
Wadhwa, PD [1 ]
Zielske, SP
Roth, JC
Ballas, CB
Bowman, JE
Gerson, SL
机构
[1] Univ Hosp Cleveland, Div Hematol Oncol, Cleveland, OH 44106 USA
[2] Univ Hosp Cleveland, Ctr Comprehens Canc, Cleveland, OH 44106 USA
[3] Case Western Reserve Univ, Cleveland, OH 44106 USA
来源
ANNUAL REVIEW OF MEDICINE | 2002年 / 53卷
关键词
tumor suppressor genes; suicide genes; dendritic cells; angiogenesis; chemotherapy-resistance genes;
D O I
10.1146/annurev.med.53.082901.104039
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Gene therapy of cancer has been one of the most exciting and elusive areas of therapeutic research in the past decade. Critical developments have occurred in gene therapy targeting cancer cells, cancer vasculature, the immune system, and the bone marrow, itself often the target for severe toxicity from therapeutic agents. We review some recent developments in the field. In each instance, clear preclinical models validated the therapeutic approach and efforts have been made to evaluate the target impact in both preclinical and early clinical trials. Although no cures can consistently be expected from today's cancer gene therapy, the rapid progress may imply that such cures are a few short years away.
引用
收藏
页码:437 / 452
页数:16
相关论文
共 88 条
[31]  
HANANIA EG, 1995, GENE THER, V2, P279
[32]   Creation of a fully functional human chimeric DNA repair protein -: Combining O6-methylguanine DNA methyltransferase (MGMT) and AP endonuclease (APE redox effector factor 1 (Ref 1)) DNA repair proteins [J].
Hansen, WK ;
Deutsch, WA ;
Yacoub, A ;
Xu, Y ;
Williams, DA ;
Kelley, MR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (02) :756-762
[33]   In situ gene therapy for adenocarcinoma of the prostate:: A phase I clinical trial [J].
Herman, JR ;
Adler, HL ;
Aguilar-Cordova, E ;
Rojas-Martinez, A ;
Woo, S ;
Timme, TL ;
Wheeler, TM ;
Thompson, TC ;
Scardino, PT .
HUMAN GENE THERAPY, 1999, 10 (07) :1239-1249
[34]  
Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/0008-6363(96)00063-6
[35]   DORMANCY OF MICROMETASTASES - BALANCED PROLIFERATION AND APOPTOSIS IN THE PRESENCE OF ANGIOGENESIS SUPPRESSION [J].
HOLMGREN, L ;
OREILLY, MS ;
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (02) :149-153
[36]   In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus [J].
Ichikawa, T ;
Tamiya, T ;
Adachi, Y ;
Ono, Y ;
Matsumoto, K ;
Furuta, T ;
Yoshida, Y ;
Hamada, H ;
Ohmoto, T .
CANCER GENE THERAPY, 2000, 7 (01) :74-82
[37]   Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors [J].
Ilan, Y ;
Prakash, R ;
Davidson, A ;
Jona, V ;
Droguett, G ;
Horwitz, MS ;
Chowdhury, NR ;
Chowdhury, JR .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (05) :1098-1106
[38]  
Im SA, 1999, CANCER RES, V59, P895
[39]   Human T lymphocyte genetic modification with naked DNA [J].
Jensen, MC ;
Clarke, P ;
Tan, G ;
Wright, C ;
Wen, CC ;
Clark, TN ;
Zhang, FY ;
Slovak, ML ;
Wu, AM ;
Forman, SJ ;
Raubitschek, A .
MOLECULAR THERAPY, 2000, 1 (01) :49-55
[40]  
Kaplan JM, 1999, J IMMUNOL, V163, P699